Absence of Fms-like tyrosine kinase 3 ligand (Flt3L) signalling protects against collagen-induced arthritis.

Absence of Fms-like tyrosine kinase 3 ligand (Flt3L) signalling protects against collagen-induced arthritis.

OBJECTIVE: Comprehending the mechanisms that regulate activation of autoreactive T cells and B cell antibody production is fundamental for understanding the breakdown in self-tolerance and development of autoimmunity. Here we studied the role of Fms-like tyrosine kinase 3 ligand (Flt3L) signalling i...

Full description

Bibliographic Details
Main Authors:	Ramos, M, Karpus, O, Broekstra, P, Aarrass, S, Jacobsen, SE, Tak, P, Lebre, M
Format:	Journal article
Language:	English
Published:	2015

Similar Items

MICE LACKING FLT3L ARE PROTECTED FROM COLLAGEN-INDUCED ARTHRITIS: REGULATING THE REGULATORS
by: Ramos, M, et al.
Published: (2012)

MICE LACKING FLT3L ARE PROTECTED FROM COLLAGEN-INDUCED ARTHRITIS: IMPAIRED T CELL FUNCTION?
by: Ramos, M, et al.
Published: (2012)

FLT3L-DEPENDENT CD103+DC ARE CRUCIAL FOR THE INITIATION AND MAINTENANCE OF COLLAGEN-INDUCED ARTHRITIS
by: Ramos, M, et al.
Published: (2013)

FLT3L-DEPENDENT CD103+DC ARE CRUCIAL FOR THE INITIATION AND MAINTENANCE OF COLAGEN-INDUCED ARTHRITIS
by: Ramos, M, et al.
Published: (2013)

In vivo evidence for an instructive role of fms-like tyrosine kinase-3 (FLT3) ligand in hematopoietic development
by: Panagiotis Tsapogas, et al.
Published: (2014-04-01)

FMS-LIKE TYROSINE KINASE (FLT3) GENE ITD MUTATION IN ACUTE MYELOID LEUKEMIA
by: Rajko Kusec, et al.
Published: (2004-12-01)

Fms-like tyrosine kinase 3 ligand controls formation of regulatory T cells in autoimmune arthritis.
by: Mattias N D Svensson, et al.
Published: (2013-01-01)

Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses
by: Roshan Pais, et al.
Published: (2019-07-01)

FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others
by: Vanessa Y.N. de Arruda, et al.

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
by: Pashtoon M. Kasi, et al.
Published: (2016-01-01)

Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
by: Bon-Kwan Koo, et al.
Published: (2024-09-01)

FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma
by: Zuoquan Zhu, et al.
Published: (2021-05-01)

Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis.
by: Mats Dehlin, et al.
Published: (2008-01-01)

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
by: Park So-Yeon, et al.
Published: (2008-07-01)

Combined effect of midostaurin and sphingosine kinase-1 inhibitor on FMS-like tyrosine kinase 3 (FLT3) wild type acute myeloid leukemia cells
by: Şahin Hande Nur, et al.
Published: (2022-02-01)

FMS-like tyrosine kinase 3 ligand treatment does not ameliorate experimental rapidly progressive glomerulonephritis.
by: Joanna R Ghali, et al.
Published: (2015-01-01)

FREQUENCY OF FMS-LIKE TYROSINE KINASE 3 KINASE DOMAIN POINT MUTATION (FLT3/TKD MUTATION) IN DIFFERENT AGE GROUPS OF ACUTE MYELOID LEUKEMIA PATIENTS.
by: Khaleeq unnisa, et al.
Published: (2014-08-01)

Discovery of natural compounds as novel FMS-like tyrosine kinase-3 (FLT3) therapeutic inhibitors for the treatment of acute myeloid leukemia: An in-silico approach
by: Uddalak Das, et al.
Published: (2025-06-01)

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia
by: Aziz Nazha, et al.
Published: (2012-08-01)

Flt3 inhibition leads to decreased production of IL-6 by synovial biopsies and fibroblast-like synoviocytes by reducing NFKb activity
by: Ramos M, et al.
Published: (2011-11-01)

Endogenous Fms-like Tyrosine Kinase-3 Ligand levels are not altered in mice after a severe burn and infection
by: Toliver-Kinsky Tracy, et al.
Published: (2009-08-01)

Neurotrophin-3 and FLT3 Tyrosine Kinase Receptor in Perinatal Life
by: Ariadne Malamitsi-Puchner, et al.
Published: (2005-01-01)

FLT3 tyrosine kinase in acute non-lymphoblastic leukemias
by: A. S. Bavykin, et al.
Published: (2022-11-01)

fms Like Tyrosine kinase3- Internal Tandem Duplication (FLT3-ITD) in Acute Myeloid Leukemia, Mutation Frequency and its Relation with Complete Remission, 2007- 2008
by: Amir Hossein Emami, et al.
Published: (2009-12-01)

fms Like Tyrosine kinase3- Internal Tandem Duplication (FLT3-ITD) in Acute Myeloid Leukemia, Mutation Frequency and its Relation with Complete Remission, 2007- 2008
by: Amir Hossein Emami, et al.
Published: (2009-10-01)

Prevalence of FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD+) in de novo acute myeloid leukemia patients categorized according to cytogenetic risk
by: Everson Augusto Krum, et al.

Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine
by: Shakyra Richardson, et al.
Published: (2021-06-01)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
by: Mark C Weir, et al.
Published: (2017-01-01)

Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia
by: Pazhakh Vahid, et al.
Published: (2011-01-01)

FMS-Like Tyrosine Kinase 3 ( FLT3 ) and Nucleophosmin 1 ( NPM1 ) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics
by: Narges Rezaei, et al.
Published: (2017-11-01)

ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application
by: Sungyoung Lee, et al.
Published: (2023-02-01)

PB1834: CLEVO: A NON-INTERVENTIONAL STUDY TO INVESTIGATE CLONAL EVOLUTION OF FMS-LIKE TYROSINE KINASE 3 (FLT3) GENE MUTATIONS DURING DISEASE PROGRESSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
by: P. Vyas, et al.
Published: (2022-06-01)

Prognostic value of serum soluble FMS-like tyrosine kinase (sFlt-1) levels in pre-eclampsia and eclampsia; a prospective cohort study
by: Ahmed M. Abbas, et al.
Published: (2018-07-01)

Rational design and synthesis of 2-(1H-indazol-6-yl)-1H-benzo[d]imidazole derivatives as inhibitors targeting FMS-like tyrosine kinase 3 (FLT3) and its mutants
by: Daseul Im, et al.
Published: (2022-12-01)

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
by: Natalie J. Hannan, et al.
Published: (2017-05-01)

Soluble fms-Like Tyrosine Kinase 1 Localization in Renal Biopsies of CKD
by: Zsuzsanna K. Zsengellér, et al.
Published: (2019-12-01)

Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells
by: Yudong Zhang, et al.
Published: (2021-06-01)

Disrupting PTPRJ transmembrane-mediated oligomerization counteracts oncogenic receptor tyrosine kinase FLT3 ITD
by: Marie Schwarz, et al.
Published: (2022-11-01)

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
by: Ruiqi Zhu, et al.
Published: (2021-05-01)

Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation.
by: Kharazi, S, et al.
Published: (2011)